How Comprehensive Genomic Profiling Is Helping Cancer Patients Today

At ESMO 2022 in Paris, oncologists discussed real-world cases and big-picture challenges

The European Society of Medical Oncology (ESMO) annual congress convened earlier this month in Paris, where, Illumina presented key abstracts demonstrating the clinical utility of comprehensiv

Illumina Grant Boosts Climate Action and Job Training

US nonprofit GRID Alternatives launches new projects to provide renewable energy

As part of Illumina’s long-term commitment to sustainability, the Illumina Corporate Foundation made a one-year, $500,000 grant to support GRID Alternatives (Generating Renewable Ideas and Development Alternatives), a nonprofit committed to increasing access to renewable energy and training people for clean energy jobs.

Illumina Accelerator Invests in the Fifth Global Funding Cycle of Startups Advancing Breakthrough Therapeutics, Diagnostics, Women's Health, and Sustainable Agriculture Applications

Six startups from Indonesia, Ireland, Israel, South Africa, United Kingdom and the United States will receive seed investment and access to technology and expertise
Press Release

SAN DIEGO, September 14, 2022 /3BL Media/ - Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it has invested in six genomics startups for the fifth global funding cycle of Illumina Accelerator in the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator is a world-class company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups. The program also announced today the October 1, 2022 application deadline for its next funding cycle.

Illumina Genomics Forum To Feature Diverse Lineup of Visionary Global Leaders

Full agenda now available for September 28–October 1 event
Press Release

SAN DIEGO, September 12, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced the release of the full agenda for its inaugural Illumina Genomics Forum. The agenda for the four-day event can be seen here.

Latest Research at ESMO Congress 2022 Showcases the Impact of Comprehensive Genomic Profiling for Cancer Patients

Presentations will include evidence on how genomic signatures and next-generation sequencing can improve the care of patients with cancer
Press Release

SAN DIEGO, September 7, 2022 / 3BL Media / — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced the upcoming presentation of multiple oncology research abstracts at this year’s European Society of Medical Oncology (ESMO) annual meeting, September 9–13 in Paris. The abstracts underscore the value of next-generation sequencing (NGS) and Illumina’s oncology assays for cancer research and patient care.

Delivering the Future of Diagnostics and Precision Oncology

At ECP 2022, Illumina presents new validation for TSO Comprehensive

At the 34th European Congress of Pathology (ECP) in Basel, Switzerland, September 3 to 7, 2022, pathologists from more than 100 countries will convene to share and gain insights on advancements in their field. Illumina Director of Product Development Victor Sementchenko will deliver a presentation during the session, Molecular Pathology Diagnostics and Translational Research Symposium.

Illumina Deepens Commitment to Customers in China With New Manufacturing Site

Investment in new Shanghai-based facility will allow the company to better serve its customers and meet growing demand
Press Release

SAN DIEGO, August 31, 2022 /3BL Media/ - Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the opening of its first manufacturing site in China. The new Shanghai-based facility enables localized production for Illumina's gene sequencing instruments and consumables and reflects the growing demand in the Chinese market for Illumina's systems and products.

Discovery Education and Illumina Corporate Foundation Present a New Virtual Field Trip for Students To Explore the Power of DNA

Press Release

CHARLOTTE, N.C., September 6, 2022 /3BL Media/ — Discovery Education and The Illumina Corporate Foundation today announced a new virtual experience – Genomics: Decoding the Language of Life Virtual Field Trip – to immerse students in grades 6-12 in the power of DNA. Presented by the Illumina Corporate Foundation and Discovery Education, this virtual field trip is part of DNA Decoded, a program designed to inspire students to unlock the power of genomics with ready-to-go, standards-aligned lessons and activities.

A New Kind of Liquid Biopsy

Canada’s STREAM project uses genomics to advance watershed health monitoring

Rivers and streams are vital to communities everywhere, for drinking water, transportation, and leisure. But pollution, drought, and climate change are taking their toll, making watershed monitoring more important every year. That’s the urgency driving the recent Illumina philanthropic grantee Sequencing the Rivers for Environmental Assessment and Monitoring (STREAM), which samples freshwater rivers throughout Canada.

Minderoo Foundation and Illumina Commit $40M AUD To Apply Advanced Genomics to Marine Conservation

New partnership will use the power of high-throughput sequencing to measure and understand marine life in our oceans at a rate that eclipses traditional research methods
Press Release

SAN DIEGO, August. 17, 2022 /3BL Media/ -- Minderoo Foundation and Illumina, Inc. (NASDAQ: ILMN), today announced a 40 million Australian dollar (US $27.8 million) partnership that will leverage the power of genomics to accelerate scientific understanding of marine systems and help marine conservationists make informed decisions. The three-year partnership demonstrates a shared commitment to conserving marine biodiversity and understanding the changing marine ecosystems on which people and national economies depend.


Subscribe to illumina